Rosetta Genomics and the Medical Dilemma of CUP

Rosetta Genomics

Rosetta Genomics

It’s a disease medical science has been battling for years. Cancer continues to claims millions of lives in the United States. But a cutting-edge technology, called MicroRNA Testing, hold promise in our collective effort to identify tumor origins. Tune-in to The Balancing Act as they discuss where this technology is…where it may be going…and how it’s helping patients and doctors defeat this dreaded disease.


The Balancing Act


Hope for CUP

We’ve all seen the pink ribbons, pink t-shirts, and even pink football gear...

We’ve all seen the pink ribbons, pink t-shirts, and even pink football gear campaigning support for Breast Cancer Awareness. However, are you familiar with CUP?

Cancer of Unknown or Uncertain Primary, aka CUP, affects a fairly significant number of people yet is relatively unheard of. These patients are diagnosed with cancer – typically late-stage or metastatic – but routine testing cannot help doctors find where the cancer started, or, the primary site. Not knowing the primary cancer type can lead to a real clinical dilemma for doctors along with emotional issues such as anxiety in patients and their loved ones.

Given the relatively large number of patients diagnosed with CUP every year, it is important to educate doctors and their patients on the fact that there are new, highly advanced, gene-based diagnostic tests that can help to identify the primary cancer with high accuracy.

Rosetta Genomics is one such company that develops microRNA-based diagnostics, and has developed a microRNA-based test called miRview® mets2 which can identify the primary site of the cancer in cases of CUP. Molecules called microRNAs, which were once considered to be “junk” DNA in fact, turn out to be master gene switches, which can literally turn genes on or off, to date, scientists have discovered approximately 2000 microRNAs.

Quick facts regarding CUP:

  • In the United States, the incidence of Cancer of Unknown or Uncertain Primary (CUP) is approximately 200,000; almost the same as breast cancer and lung cancer.
  • Selection of primary cancer targeted therapy can increase survival, improve quality of life, and may be more cost effective.
  • Cancer of Unknown or Uncertain Primary (CUP) does not have to remain “unknown” or “uncertain”.
  • CUP patients are encouraged to find out more about advanced medical diagnostics on the Internet, and ask their doctor if they are appropriate for them.

“We believe it is very important to educate both physicians and their patients on new cutting-edge developments in molecular diagnostics. The miRview® mets2 assay can help identify the primary origin in patients with Cancer of Unknown or Uncertain Primary, which enables the physician to select the most effective therapy”, said Ken Berlin, President and CEO of Rosetta Genomics.

Advanced gene-based tests are available to alleviate a patient’s fear of the unknown and to provide hope for improved survival.

Please tune in to the Balancing Act on February 4th, February 27th and March 5th as Dr. E. Robert Wassman talks about CUP and Rosetta Genomics’ cutting-edge technologies.


Balancing Act Talks Medical Dilemma of CUP on Lifetime TV

FOR IMMEDIATE RELEASE

Media Contact:
O2 Media, Inc.
pamela@o2mediainc.com
(954) 691-1102

The Balancing Act Talks Medical Dilemma of CUP on Lifetime TV

Rosetta Genomics, HojiBlanca, Rushmore SuperFoods, Navajo Pride, Bioventus, Maruchan Take Center Stage on Upcoming Show

(Pompano Beach, FL – PR LOG – January 29, 2013) To kick off the New Year, popular morning show The Balancing Act® highlights a cutting-edge technology in the world of diagnosing cancer along with information about natural foods and drinks on Monday, February 4th at 7:00 a.m. (ET/PT) on Lifetime TV. Make sure to watch as hosts Danielle and Kristy help jump start the day with animated conversation and lively demonstrations – all to balance and empower a woman’s life.

Don’t miss this featured segment taking center stage on The Balancing Act®:

• Hope for CUP with Rosetta Genomics – Are you familiar with CUP? In the U.S. the incidence of Cancer of Unknown or Uncertain Primary (CUP) is approximately 200,000; almost the same as breast cancer and lung cancer. Patients are diagnosed with cancer – typically late-stage or metastatic – but routine testing cannot help doctors find where the cancer started, or, the primary site. But a cutting-edge technology, called MicroRNA Testing from Rosetta Genomics, holds promise in their collective effort to identify tumor origins. Tune-in to The Balancing Act® as Dr. E. Robert Wassman talks about where this technology is…where it may be going…and how it’s helping patients and doctors defeat this dreaded disease.

“We believe it is very important to educate both physicians and their patients on new cutting-edge developments in molecular diagnostics. The miRview® mets2 assay can help identify the primary origin in patients with Cancer of Unknown or Uncertain Primary, which enables the physician to select the most effective therapy”, said Ken Berlin, President and CEO of Rosetta Genomics. http://www.mirviewdx.com.

Back by popular demand, these segments complete the line-up:

• Ingredients for Heart Healthy Cooking with HojiBlanca Extra Virgin Olive Oil
• RE-Think Energy Drinks with Revive and Revitalize from Rushmore Superfoods
• Healthy Traditional Foods from Navajo Agricultural Products
• Relief for Knee Osteoarthritis Pain with SUPARTZ® from Bioventus
• Create a Classic Spanish Dish with an Oriental Twist with Yakisoba entrees from Maruchan

The Balancing Act® on Lifetime Television
Now in its 5th year, The Balancing Act® continues to empower women in all aspects of their lives. The mission at The Balancing Act® is simple. The show strives to help today’s modern woman balance it all by bringing them exceptional solutions to everyday problems. Entertaining, educational and trusted by women, America’s premier morning show The Balancing Act® airs weekday mornings on Lifetime television at 7:30 am (ET/PT).

For more information please contact us at: http://www.TheBalancingAct.com
Like us on Facebook at: https://www.facebook.com/TheBalancingActFans
Follow us on Twitter at: http://twitter.com/#!/balancingacttv